Revolutionizing Healthcare: The Future of Artificial Blood Technology
The development of artificial blood for widespread use is progressing, with clinical trials currently taking place at Nara Medical University in Japan. The prototype, made from hemoglobin molecules from expired donor blood, has shown promising results with no significant side effects. This artificial blood, encapsulated in protective lipid shells, functions like regular blood by carrying oxygen throughout the body.
Unlike human blood, the artificial blood being tested in Japan does not require matching blood types for transfusions. Similar to Type O- blood, this manufactured blood is considered compatible with any blood type. Additionally, artificial blood has a longer shelf life of up to two years, compared to organic blood, which can only be stored for 42 days.
The development of artificial blood is seen as a potential solution to address chronic blood bank shortages, particularly in underdeveloped regions where access to blood can be a matter of life and death. Nara Medical University aims to introduce its artificial blood product by 2030, pending the successful completion of its ongoing clinical trials.
In conclusion, the advancement of artificial blood technology holds great promise for addressing critical issues related to blood supply shortages and compatibility challenges. With the potential to revolutionize transfusion practices, artificial blood could significantly impact healthcare delivery worldwide.